[{"orgOrder":0,"company":"Spine BioPharma","sponsor":"Viscogliosi Bros.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Peptide","year":"2022","type":"Series B Financing","leadProduct":"SB-01","moa":"TGF beta-1","graph1":"Neurology","graph2":"Phase III","graph3":"Spine BioPharma","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Intradiscal injection","sponsorNew":"Spine BioPharma \/ Viscogliosi Bros.","highestDevelopmentStatusID":"10","companyTruncated":"Spine BioPharma \/ Viscogliosi Bros."},{"orgOrder":0,"company":"Spine BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"SB-01","moa":"TGF beta-1","graph1":"Neurology","graph2":"Phase II","graph3":"Spine BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intradiscal injection","sponsorNew":"Spine BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Spine BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"Spine BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"SB-01","moa":"TGF beta-1","graph1":"Neurology","graph2":"Phase III","graph3":"Spine BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Spine BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Spine BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"Spine BioPharma","sponsor":"Ensol BioSciences","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Peptide","year":"2024","type":"Agreement","leadProduct":"SB-01","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Spine BioPharma","amount2":0.16,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Spine BioPharma \/ Spine BioPharma","highestDevelopmentStatusID":"14","companyTruncated":"Spine BioPharma \/ Spine BioPharma"},{"orgOrder":0,"company":"Spine BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"SB-01","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Spine BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Spine BioPharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Spine BioPharma \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Spine BioPharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : SB-01 is a 7-amino acid synthetic peptide that binds to and antagonizes TGF-Beta activity. It is being developed for chronic low back pain in degenerative disc disease.

                          Brand Name : SB-01

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          September 24, 2024

                          Lead Product(s) : SB-01

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Spine BioPharma acquired the right to develop and commercialize SB-01, excluding Korea. It is being evaluated for the treatment of pain-related disability, associated with Degenerative Disc Disease.

                          Brand Name : SB-01

                          Molecule Type : Peptide

                          Upfront Cash : Undisclosed

                          July 10, 2024

                          Lead Product(s) : SB-01

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase III

                          Recipient : Ensol BioSciences

                          Deal Size : $155.0 million

                          Deal Type : Agreement

                          blank

                          03

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : SB-01 is a 7-amino acid peptide that binds to and antagonizes TGFβ1 activity. TGFβ1 is an inflammatory cytokine which is often highly expressed in the degenerated discs.

                          Brand Name : SB-01

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          September 07, 2022

                          Lead Product(s) : SB-01

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : SB-01 is a 7-amino acid peptide that binds to and antagonizes TGFβ1 activity, is the first pharmacologic treatment to enter Phase 3 studies for the treatment of pain-related disability, associated with DDD.

                          Brand Name : SB-01

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 11, 2022

                          Lead Product(s) : SB-01

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : The company intends to use the financing to support further development of SB-01 For Injection "SB-01" (formerly referred to as Remedisc™), a first-in-class therapeutic for the treatment of degenerative disc disease.

                          Brand Name : Remedisc

                          Molecule Type : Peptide

                          Upfront Cash : Undisclosed

                          March 28, 2022

                          Lead Product(s) : SB-01

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Viscogliosi Bros.

                          Deal Size : $13.0 million

                          Deal Type : Series B Financing

                          blank